Collectively, SA integrates peptide-guided molecular targeting with nano-Se-enabled delivery, establishing a multifunctional platform that accelerates HSC70-dependent lysosomal degradation of PD-L1, disrupts immune-evasion mechanisms, thereby augmenting the effectiveness of cancer immunotherapy (Figure 1). The gene discussed is HSPA8; the disease is cancer.